EDWARDS LIFESCIENCES EDWARDS INSPIRIS RESILIA AORTIC VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE
|
Back to Search Results |
|
Model Number 11500A |
Device Problems
Calcified (1077); Insufficient Information (3190)
|
Patient Problems
Heart Failure/Congestive Heart Failure (4446); Insufficient Information (4580)
|
Event Date 12/01/2022 |
Event Type
Injury
|
Manufacturer Narrative
|
The subject device is not available for evaluation, as it remains implanted in the patient.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
|
Event Description
|
It was reported that a patient with a 25mm 11500a aortic valve underwent a valve-in-valve procedure after an unknown implant duration due to unknown reason.The tavr was performed with a 29mm 9600tfx transcatheter valve.
|
|
Manufacturer Narrative
|
Updated sections: b5, b7, d4 model number, serial number and udi number, d6a.G3, g6, h6 component code, health effect - clinical code, and device code(s).
|
|
Event Description
|
It was reported that a patient with a 25mm 11500a aortic valve implanted for 2 years and 3 months underwent a valve-in-valve procedure due to calcification.The patient presented with heart failure and shortness of breath and fatigue.The tavr was performed with a 29mm 9600tfx transcatheter valve.The patient outcome at the end of the procedure as stable and discharged to home on pod#1.
|
|
Manufacturer Narrative
|
Updated sections: d4 expiration date, g3, g6, h4, h6 type of investigation, investigation findings, and investigation conclusions.The device history record was reviewed and shows that this device met all manufacturing specifications for product release prior to distribution.No issues were identified that would have impacted this event.Calcific degeneration is a common cause of bioprosthetic heart valve failures.Many factors contribute to the onset and propagation of calcification.These include patient factors (age, disease state, pharmacological intervention, etc.), mechanical stress related to the valve's hemodynamic performance, and glutaraldehyde fixation of tissue.Of these, the fixation process is a relatively minor contributor to calcification for edwards' tissue valves due to anti-calcification treatments during manufacturing.Though numerous studies have been conducted on preventive calcification strategies in bioprosthetic heart valves, the causes of calcification are not fully understood and there are still no mechanisms or medical therapies which fully prevent bioprostheses from calcifying.Through further investigation, it was determined that a definitive root cause cannot be conclusively determined; however, patient factors likely caused or contributed.
|
|
Search Alerts/Recalls
|
|
|